Compare A O Smith Corp (AOS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
A O Smith Corp vs Pfizer Inc — how do they compare? A O Smith Corp trades at $62.54 (market cap $8.65B), while Pfizer Inc trades at $26.29 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 17.5× A O Smith Corp's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| AOS | PFE | |
|---|---|---|
Market Cap | $8.65B | $151.73B |
Sector | Industrials | Health |
52-Week High | $80.47 | $28.56 |
52-Week Low | $55.78 | $23.60 |
Enterprise Value | $9.15B | $203.22B |
Dividend Yield | 2.26% | 6.46% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOS trades at $62.41, down 2.45% today, with a bullish technical signal from moving averages and key support at $60. The company reported Q2 2026 EPS of $1.03, beating estimates, driven by North America strength. Revenue remains stable at $3.83B for 2025, with strong profitability margins including a 38.59% gross margin and 14.26% net income margin. Recent leadership transition saw Kevin Wheeler retire as Executive Chairman, with Stephen Shafer taking over.
The stock offers a 7.8% upside to the $67.25 consensus price target, supported by solid cash flow and a dividend yield. Risks include exposure to input cost pressures and weaker China demand, as noted in Q2 results. Analyst sentiment is mixed with 33% buy ratings, but institutional selling by Amundi in Q1 2026 warrants monitoring for momentum shifts.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
